0.70
-0.0628(-8.23%)
Currency In USD
Address
2080 Century Park East
Los Angeles, CA 90067
United States of America
Phone
305 918 1980
Website
Sector
Healthcare
Industry
Biotechnology
Employees
25
First IPO Date
February 07, 2018
| Name | Title | Pay | Year Born |
| Mr. David H. Weinstein | Chief Executive Officer & Director | 0 | 1960 |
| Mr. Simon Tarsh | Interim Chief Financial Officer | 306,000 | 1961 |
| Dr. Francois Binette M.Sc., Ph.D. | Chief Operating Officer and Executive Vice President for Research & Development | 402,500 | 1964 |
| Dr. Serhat Gümrükcü | Co-Founder & Inventor | 0 | N/A |
| Mr. Greg Duczynski Ph.D. | Senior Vice President for Clinical Operations | 0 | N/A |
Renovaro Biosciences Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV. It also develops RENB-DC-11, an allogeneic dendritic cell therapeutic vaccine for pancreatic cancer; RENB-DC-12-XX, an allogeneic dendritic cell therapeutic vaccine for other solid tumors; and RENB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. It has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was formerly known as Enochian Biosciences, Inc. and changed its name to Renovaro Biosciences Inc. in August 2023. Renovaro Biosciences Inc. is headquartered in Los Angeles, California.